Docetaxel Chemo Ups Survival in High-Risk Localized Prostate Cancer
THURSDAY, March 28, 2019 -- Adding docetaxel-based chemotherapy (CT) to standard treatment for high-risk nonmetastatic prostate cancer improves survival, according to a study published online March 12 in the Journal of Clinical Oncology.
Seth A....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Pharmaceuticals | Prostate Cancer | Study | Taxotere